Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Akt
    (5)
  • Apoptosis
    (12)
  • Autophagy
    (4)
  • Caspase
    (4)
  • ERK
    (56)
  • Endogenous Metabolite
    (4)
  • JNK
    (4)
  • MEK
    (8)
  • NF-κB
    (11)
  • Others
    (6)
Filter
Search Result
Results for "extracellular signal regulated kinases" in TargetMol Product Catalog
  • Inhibitor Products
    66
    TargetMol | Activity
  • Natural Products
    26
    TargetMol | inventory
  • Recombinant Protein
    1
    TargetMol | natural
SCH772984
T6066942183-80-4
SCH 772984 is a potent inhibitor of ERK1/ERK2 (IC50: 4/1 nM) and has only weak inhibitory for other 300 tested kinases.
  • $48
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
magnolin
T385731008-18-1
Magnolin reduces the renal oxidative stress, suppresses caspase-3 activity, and increases Bcl-2 expression in vivo and in vitro. Magnolin has anti-inflammatory and antioxidative effects.
  • $93
In Stock
Size
QTY
Astragaloside IV
T297384687-43-4
Astragaloside IV (AS-IV), an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells. Astragaloside IV is a bioactive saponin first isolated from the dried plant roots of the genus Astragalus, which is used in traditional Chinese medicine.1 It dose-dependently inhibits human adenovirus type 3 (HAdV-3) in A549 cells (IC50 = 23 μM; LC50 = 865 μM).It inhibits replication of HAdV-3 and decreases HAdV-3-induced apoptosis. It has diverse protective effects for the cardiovascular, immune, digestive, and nervous systems. In particular, it reduces myocardial infarct size in dogs when administered prior to coronary ligation and reduces reperfusion arrhythmias in isolated rat hearts.
  • $32
In Stock
Size
QTY
TargetMol | Citations Cited
Epieriocalyxin A
TN3967191545-24-1
Epieriocalyxin A can suppress Caco-2 colon cancer cell growth. It could be a potential drug for colon cancer therapy in the future.
  • $216
In Stock
Size
QTY
TargetMol | Inhibitor Sale
EF24
T27242342808-40-6In house
EF24 (3,5-Bis[(2-fluorophenyl)Methylene]-4-piperidinone) treatment increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK. EF24 shows potent anti-tumor activity in oral squamous cell carcinoma (OSCC) via deactivation of the MAPK/ERK signaling pathway.
  • $33
In Stock
Size
QTY
Lidocaine hydrochloride
T114473-78-9
Lidocaine hydrochloride (Lignocaine hydrochloride) is a local anesthetic and cardiac depressant used as an antiarrhythmic agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
  • $45
In Stock
Size
QTY
TargetMol | Citations Cited
Tauroursodeoxycholate sodium
T699335807-85-3
Tauroursodeoxycholate sodium (TUDC) is an endoplasmic reticulum (ER) stress inhibitor, used for the treatment of gallstones and liver cirrhosis.
  • $30
In Stock
Size
QTY
TargetMol | Citations Cited
Temuterkib
T40911951483-29-6
Temuterkib (LY3214996) is a potent and selective, orally available inhibitor of the extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity.
  • $64
In Stock
Size
QTY
TargetMol | Citations Cited
Honokiol
T300135354-74-6
Honokiol (NSC-293100) is the active principle of magnolia extract. It inhibits the activation of Akt and enhances the phosphorylation of ERK1/ERK2.
  • $50
In Stock
Size
QTY
TargetMol | Citations Cited
Ulixertinib
T7005869886-67-9
Ulixertinib (VRT752271) (BVD-523, VRT752271) is an effective and reversible ERK1/ERK2 inhibitor. The IC50 of Ulixertinib is less than 0.3 nM for ERK2.
  • $34
In Stock
Size
QTY
TargetMol | Citations Cited
Bohemine
T2029189232-42-6
Bohemine is a cyclin-dependent kinase inhibitor.
  • $47
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
PD98059
T2623167869-21-8
PD98059 is an MEK inhibitor that inhibits MEK1 and MEK2 (IC50=2/50 μM) and is non-ATP-competitive. PD98059 is also antagonistic as a ligand for AHR. PD98059 inhibits autophagy.
  • $34
In Stock
Size
QTY
TargetMol | Citations Cited
Tauroursodeoxycholate
T253214605-22-2
Tauroursodeoxycholate (UR 906), also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.
  • $50
In Stock
Size
QTY
TargetMol | Citations Cited
Ravoxertinib
T65111453848-26-4
Ravoxertinib (GDC-0994) is an effective and orally available ERK1/2 inhibitor (IC50: 1.1/0.3 nM).
  • $34
In Stock
Size
QTY
TargetMol | Citations Cited
FR 180204
T1956865362-74-9
FR 180204 is a potent and selective ATP-competitive inhibitor of ERK1 and ERK2.
  • $36
In Stock
Size
QTY
TargetMol | Citations Cited
Lidocaine Hydrochloride hydrate
T1144L6108-05-0
Lidocaine Hydrochloride hydrate is an amide local anesthetic, has anti-inflammatory property.
  • $54
In Stock
Size
QTY
TargetMol | Inhibitor Sale
MK-8353
T120691184173-73-6
MK-8353 (SCH900353) is a potent, selective and orally available inhibitor of ERK1/2 (IC50s of 23.0 nM and 8.8 nM, respectively)
  • $73
In Stock
Size
QTY
SEW​2871
T2171256414-75-2
SEW 2871 is an orally available, highly selective S1P1 agonist with an EC50 of 13.8 nM.It reduces the number of lymphocytes in the blood and is used in studies related to diabetes, Alzheimer's disease, liver fibrosis, and inflammation. It activates ERK, Akt and Rac signaling pathways and induces S1P1 internalization and recycling.
  • $48
In Stock
Size
QTY
6-OAU
T203683797-69-7
6-OAU (GTPL5846)(GTPL5846; 6-n-octylaminouracil) is a surrogate agonist of GPR84; activates human GPR84 in the presence of Gqi5 chimera in HEK293 cells with an EC50 of 105 nM in the PI assay.
  • $163
In Stock
Size
QTY
Rineterkib
T112241715025-32-3
Rineterkib (ERK-IN-1) is an inhibitor of RAF and ERK1/2 activating mutations in the MAPK pathway.
  • $96
In Stock
Size
QTY
TargetMol | Citations Cited
TRPM4 inhibitor 8
T97761353979-43-7
TRPM4 inhibitor 8 is an inhibitor of Transient receptor potential melastatin 4(TRPM4) which contributes to viability, migration, cell cycle shift, and adhesion.
  • $39
In Stock
Size
QTY
Gynosaponin TN2
TN735077658-95-8
Gynosaponin TN-2, demonstrating anti-Parkinsonian activity, mitigates L-DOPA (100 and 200 μM)-induced apoptotic cell death in pheochromocytoma 12 cells through the modulation of extracellular signal-regulated protein kinases 1 and 2 activation.
  • Inquiry Price
Size
QTY
Yoda 1
T7506448947-81-7
Yoda1 is a Piezo1 ion channel agonist (EC50s = 17.1 and 26.6 μM for murine and human Piezo1-transfected HEK293T cells, respectively)
  • $39
In Stock
Size
QTY
TargetMol | Citations Cited
Isoacteoside
T389261303-13-7
Isoacteoside has the anti-inflammatory effect, mediated by action on caspase-1, mitogen-activated protein kinases (c-Jun N-terminal kinase, p38, extracellular signal-regulated protein kinase) and nuclear factor-kappa B pathways.
  • $65
In Stock
Size
QTY
Asperulosidic acid
TN141025368-11-0
Asperulosidic acid (ASPA) has anti-tumor, anti-oxidant, and anti-inflammatory activities. ASPA is related to the inhibition of inflammatory cytokines (TNF-α, IL-6) and mediators via suppression of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways.
  • $156
In Stock
Size
QTY
TargetMol | Citations Cited
Sulforaphene
TL0016592-95-0
Sulforaphene is a natural product isolated from radish seeds, exhibits an ED50 against velvetleaf seedlings approximately 2 x 10 -4 M. Sulforaphene promotes cancer cells apoptosis and inhibits migration via inhibiting EGFR, p-ERK1/2, NF‐κB and other signa
  • $31
In Stock
Size
QTY
Deltonin
T384455659-75-1
Deltonin has an inhibition of ERK1/2 and AKT activation. Deltonin shows cytotoxicity against human HepG2 cells (IC50: 7.66 μM), mouse C26 cells (IC50: 1.22 μM), and human MDA-MB-231 cells (IC50: 1.58 μM).
  • $125
In Stock
Size
QTY
XMD17-109
T18421435488-37-1
XMD17-109 (ERK5-IN-1) is a new selective ERK-5 inhibitor (EC50: 4.2 uM, HEK293 cells).
  • $35
In Stock
Size
QTY
AX-15836
T143602035509-96-5
AX-15836 is an inhibitor of ERK5 (IC50 : 8 nM).
  • $52
In Stock
Size
QTY
Loureirin B
T3876119425-90-0
Loureirin B can downregulate the expression of fibrosis-related molecules by regulating MMPs and TIMPs levels, inhibit scar fibroblast proliferation and suppress TGF-β1-induced fibrosis, during which TGF-β1/Smad2/3 pathway is likely involved.
  • $64
In Stock
Size
QTY
XMD8-92
T18431234480-50-2
XMD8-92 is an effective and specific BMK1/ERK5 inhibitor (Kd: 80 nM).
  • $48
In Stock
Size
QTY
Tizaterkib
T104292097416-76-5
Tizaterkib (AZD-0364) is a potent and selective ERK2 inhibitor.
  • $96
In Stock
Size
QTY
Corynoxeine
T6S0655630-94-4
1. Corynoxeine is a potent ERK1/2 inhibitor of key PDGF-BB-induced VSMC proliferation and may be useful in the prevention and treatment of vascular diseases and restenosis after angioplasty.
  • $40
In Stock
Size
QTY
Gypenoside L
TN172194987-09-4
Gypenoside L inhibits autophagic flux and induces cell death in human esophageal cancer cells through endoplasm reticulum stress-mediated Ca2+ release. It also inhibit non-small cell lung carcinoma A549 cell inhibitory activity.
  • $128
In Stock
Size
QTY
DMU-212
T36674134029-62-2
DMU-212 is a methylated derivative of Resveratrol , with antimitotic, anti-proliferative, antioxidant and apoptosis promoting activities. DMU-212 induces mitotic arrest via induction of apoptosis and activation of ERK1/2 protein. DMU-212 has orally active[1][2]. DMU-212 (0.3125-40 μM) inhibits growth of A375, MeWo, Bro and M5 cells human melanoma cells[1].DMU-212 (30-50 μM; 24 hours) induces upregulation of cell cycle inhibitors, apoptosis and ERK activation in A375 cells[1].DMU-212 induces upregulation of cell cycle inhibitors, apoptosis and ERK activation in A375 cells[1].DMU-212 induces G2/M arrest and apoptosis in cancer cells[1].DMU-212 induces mitotic arrest, apoptosis and activation of ERK1/2 protein[1]. Cell Proliferation Assay[1] Cell Line: A375 cells, MeWo cells, M5 cells, Bro cells DMU-212 (50 mg/kg; i.g.; three times a week; for 14 days) inhibits tumor growth in xenograft model of human ovarian cancer[2]. Animal Model: 6-weeks-old SCID female mice (20-24 g), with ovarian cancer xenografts[2] [1]. Vasilis Pericles Androutsopoulos, et al. Activation of ERK1/2 is required for the antimitotic activity of the resveratrol analogue 3,4,5,4'-tetramethoxystilbene (DMU-212) in human melanoma cells. Exp Dermatol. 2015 Aug;24(8):632-4. [2]. Hanna Piotrowska, et al. DMU-212 inhibits tumor growth in xenograft model of human ovarian cancer. Biomed Pharmacother. 2014 May;68(4):397-400.
  • $30
In Stock
Size
QTY
KO-947
TQ00051695533-89-1
KO-947 is a potent and specific inhibitor of ERK1/2 kinases.
  • $54
In Stock
Size
QTY
CC-90003
T148941621999-82-3
CC-90003 is a selective inhibitor of ERK 1/2. It has antitumor activity.
  • $51
In Stock
Size
QTY
CAFESTOL
T5727469-83-0
CAFESTOL is a ERK inhibitor for AP-1-targeted activity against PGE2 production and the mRNA expression of cyclooxygenase (COX)-2 in LPS-activated RAW264.7 cells. Cafestol has strong inhibitory activity on PGE2 production by suppressing the NF-kB activation pathway.
  • $32
In Stock
Size
QTY
Methylnissolin
TN235473340-41-7
Methylnissolin is a natural product isolated from Astragalus membranaceus that inhibits platelet-derived growth factor (PDGF)-BB-induced cell proliferation with an IC50 of 10 μM. It inhibits PDGF-BB-induced vascular smooth muscle cell proliferation by inhibiting the ERK1/2 MAP kinase cascade. It also inhibits PDGF-BB-induced phosphorylation of extracellular signal-regulated kinase 1/2 (ERIC1/2) mitogen-activated protein (MAP) kinases and has antibacterial and anticancer effects.
  • $81
In Stock
Size
QTY
Tenuifoliside A
T3856139726-35-5
Tenuifoliside A has anti-apoptotic , neuroprotective activity. And tenuifoliside A has anti-inflammatory effect, which is mediated by the inhibition of the NF-κB and MAPK pathways.
  • $68
In Stock
Size
QTY
VX-11e
T3166896720-20-0
VX-11e (TCS ERK 11e) is a potent, selective, and orally bioavailable ERK(Extracellular Signal-Regulated Kinase) inhibitor; antitumor agent.
  • $50
In Stock
Size
QTY
ERK5-IN-2
T55351888305-96-1
ERK5-IN-2 is an orally active, sub-micromolar, selective ERK5 inhibitor with IC50s of 0.82 μM, 3 μM for ERK5 and ERK5 MEF2D, respectively.
  • $41
In Stock
Size
QTY
DEL-22379
T6818181223-80-3
DEL-22379 is a water-soluble ERK dimerization inhibitor with IC50 of ~0.5 μM.
  • $30
In Stock
Size
QTY
Urolithin B
T132651139-83-9
Urolithin B is one of the gut microbial metabolites of ellagitannins and is found in diverse plant foods, including pomegranates, berries, walnuts, tropical fruits, and medicinal herbs. Urolithin B inhibits NF-κB activity by reducing the phosphorylation and degradation of IκBα, and suppresses the phosphorylation of JNK, ERK, and Akt, and enhances the phosphorylation of AMPK. Urolithin B is also a regulator of skeletal muscle mass. Urolithin B has anti-inflammatory and antioxidant effects.
  • $39
In Stock
Size
QTY
Lidocaine
T0468137-58-6
Lidocaine (Alphacaine) is an amide local anesthetic with anti-inflammatory properties in vitro and in vivo. It has this functions perhaps due to an attenuation of intracellular adhesion molecule-1 (ICAM-1), pro-inflammatory cytokines, and reduction of neutrophils influx.
  • $45
In Stock
Size
QTY
ERK-IN-3
T91412055597-12-9
ERK-IN-3 (ASN007 free base) is a potent and orally active inhibitor of ERK. It inhibits ERK1/2 with low single-digit nM IC50 values. It can be used for the research of cancers driven by RAS mutations.
  • $56
In Stock
Size
QTY
Nitidine chloride
T5S076113063-04-2
1. Nitidine chloride has inhibitory effects on various tumors, such as renal cancer , breast cancer. 2. Nitidine chloride inhibits the proliferation of SMMC-7721 cells in vitro in a time- and dose-dependent manner and identifies efficacy in vivo in a mouse model of HCC.
  • $30
In Stock
Size
QTY
Mogrol
TN234688930-15-8
Mogrol, a biometabolite of mogrosides, functions by inhibiting the ERK1/2 and STAT3 pathways, diminishing CREB activation, and activating AMPK signaling.
  • $51
In Stock
Size
QTY
AG126
T4092118409-62-4
AG126 (Tyrphostin AG126) selectively inhibits the phosphorylation of ERK1 (p44) and ERK2 (p42) at 25-50 μM. It blocks the production of TNF-α in vitro2 and in vivo, attenuating signaling through NF-κB, the induced expression of COX-2 and iNOS, and the inflammatory response in diverse animal models. AG-126 weakly inhibits epidermal GFRK (IC50: 450 μM) and platelet-derived GFRK (IC50 > 100 μM).
  • $30
In Stock
Size
QTY
CAY10561
T36672933786-58-4
The extracellular signal-regulated kinase (ERK) signal transduction pathway regulates a diverse array of cellular processes. These processes include cell survival, proliferation, motility, and differentiation and are constitutively activated in cancers involving lung, colon, pancreas, kidney, and ovary. CAY10561 is a potent, ATP-competitive inhibitor of ERK2 (Ki = 2 nM). This compound is highly selective for ERK2 compared to other kinases such as PKA (Ki = 0.39 μM) and JNK3 (Ki = 4 μM). CAY10561 inhibits proliferation of COLO 205 cells with an IC50 value of 0.54 μM.
  • $65
35 days
Size
QTY